BioAtla (BCAB) Cash from Operations (2020 - 2026)
BioAtla (BCAB) posted quarterly Cash from Operations of 5267000.0 for Q1 2026, up 67.66% year-over-year from 3141414.77 in Q1 2025, and up 33.46% quarter-over-quarter from 7915000.0 in Q4 2025.
BioAtla (BCAB) Cash from Operations (2020 - 2026) Analysis & Trends
BioAtla's Cash from Operations history runs 7 years deep, the most recent figure standing at 5267000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 67.66% year-over-year to 5267000.0; the TTM figure through Mar 2026 stood at 37183000.0 (up 35.22% YoY), while the FY2025 annual figure was 48204000.0, up 32.99% from the prior year.
- Cash from Operations for Q1 2026 stood at 5267000.0, up from 7915000.0 in the prior quarter.
- The five-year high for Cash from Operations was 5132000.0 in Q3 2024, with the low at 30828000.0 in Q1 2024.
- The 5-year median for Cash from Operations is 19193000.0 (2024), against an average of 18814235.29.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 81.23% in 2024, then tumbled 92.54% in 2025.
- BioAtla's Cash from Operations stood at 24347000.0 in 2022, then retreated by 22.9% to 29922000.0 in 2023, then surged by 43.91% to 16783000.0 in 2024, then jumped by 52.84% to 7915000.0 in 2025, then soared by 33.46% to 5267000.0 in 2026.
- Business Quant data shows BCAB's Cash from Operations at 5267000.0 in Q1 2026, 7915000.0 in Q4 2025, and 9881000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 728.46 Mn |
| 10 | BioAtla | 5.51 Mn | 5.51 Mn | - | -419,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -419,000.00 |
| Jun 30, 2026 | -419,000.00 |
| Mar 31, 2026 | -5.27 Mn |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Sep 30, 2025 | -9.88 Mn |
| Sep 30, 2025 | -9.88 Mn |
| Jun 30, 2025 | -14.12 Mn |
| Jun 30, 2025 | -14.12 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Dec 31, 2024 | -16.78 Mn |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -19.19 Mn |
| Jun 30, 2024 | -19.19 Mn |
| Mar 31, 2024 | -30.83 Mn |
| Mar 31, 2024 | -30.83 Mn |